Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

Virginia L Stauffer, Ira Turner, Phebe Kemmer, William Kielbasa, Kathleen Day, Martha Port, Tonya Quinlan, Angelo Camporeale, Virginia L Stauffer, Ira Turner, Phebe Kemmer, William Kielbasa, Kathleen Day, Martha Port, Tonya Quinlan, Angelo Camporeale

Abstract

Background: Migraine clinical profile may change with age, making it necessary to verify that migraine treatments are equally safe and effective in older patients. These analyses evaluated the effects of patient age on the pharmacokinetics (PK), efficacy, and safety of galcanezumab for prevention of migraine.

Methods: Analyses included efficacy data from three double-blind phase 3 clinical trials: two 6-month studies in episodic migraine (EVOLVE-1, EVOLVE-2: N = 1773) and one 3-month study in chronic migraine (REGAIN:N = 1113). Patients were randomized 2:1:1 to placebo, galcanezumab 120 mg, or galcanezumab 240 mg. Safety and PK data included additional phase 2 and phase 3 trials for a larger sample size of patients > 60 years (range = 18-65 for all studies). Subgroup analyses assessed efficacy measures, adverse event (AE) occurrence, and cardiovascular measurement changes by patient age group. Galcanezumab PK were evaluated using a population analysis approach, where age was examined as a potential covariate on apparent clearance (CL/F) and apparent volume of distribution (V/F) of galcanezumab.

Results: Numbers of baseline monthly migraine headache days were similar across age groups. There were no statistically significant treatment-by-age group interactions for any efficacy measures, except in episodic migraine studies where older patients appeared to have a larger reduction than younger patients in the number of monthly migraine headache days with acute medication use. Age (18-65) had a minimal effect on CL/F, and no effect on V/F. Galcanezumab-treated patients ≥60 years experienced no clinically meaningful increases in blood pressure and no increased frequency in treatment-emergent AEs, discontinuations due to AEs, serious adverse events (SAEs) overall, or cardiovascular SAEs, compared to age-matched placebo-treated patients.

Conclusions: Age (up to 65 years) does not affect efficacy in migraine prevention and has no clinically meaningful influence on galcanezumab PK to warrant dose adjustment. Furthermore, older galcanezumab-treated patients experienced no increases in frequency of AEs or increases in blood pressure compared with age-matched placebo-treated patients.

Trial registrations: EVOLVE-1 (NCT02614183, registered 23 November 2015), EVOLVE-2 (NCT02614196, 23 November 2015), REGAIN (NCT02614261, 23 November 2015), ART-01 (NCT01625988, 20 June 2012, ), I5Q-MC-CGAB (NCT02163993, 12 June 2014, ), I5Q-MC-CGAJ (NCT02614287, 23 November 2015, ), all retrospectively registered.

Keywords: Aging population; CGRP antagonist; Elderly; Galcanezumab; Migraine; Migraine in older adults; Migraine prevention; Migraine prophylaxis; Monoclonal antibody.

Conflict of interest statement

VLS is an employee of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.

IT has received grants from Allergan, Amgen, Biohaven, ElectroCore, Eli Lilly and Company, Lundbeck (Alder), Nerivio, and Teva. He has received payments for speaking and/or consulting from Allergan, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Headache Cooperative of New England, Nerivio, Novartis, Revance, Teva, and The Headache Institute. IT received non-financial support from Eli Lilly and Company.

PK is an employee of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.

WK is an employee of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.

KD is an employee of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.

MP is an employee of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.

TQ is an employee of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.

AC is an employee of Eli Lilly and Company and/or one of its subsidiaries, Indianapolis, IN, USA and is a minor stockholder of Eli Lilly and Company.

Figures

Fig. 1
Fig. 1
Effect of age (18–65 years) on galcanezumab CL/F and V/F
Fig. 2
Fig. 2
Reduction in migraine headache days and migraine headache days with acute medication, by age group
Fig. 3
Fig. 3
Percentages of patients with ≥50% and ≥75% reductions in migraine headache days, by age group

References

    1. Eli Lilly and Company . Emgality Highlights of Prescribing Information. 2018.
    1. Eli Lilly and Company . Emgality Summary of Product Characteristics. 2018.
    1. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088. doi: 10.1001/jamaneurol.2018.1212.
    1. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454. doi: 10.1177/0333102418779543.
    1. Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2e21. doi: 10.1212/WNL.0000000000006640.
    1. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45(Suppl 1):S3–S13. doi: 10.1111/j.1526-4610.2005.4501001.x.
    1. Haan J, Hollander J, Ferrari MD. Migraine in the elderly: a review. Cephalalgia. 2007;27(2):97–106. doi: 10.1111/j.1468-2982.2006.01250.x.
    1. Mattsson P, Svardsudd K, Lundberg PO, Westerberg CE. The prevalence of migraine in women aged 40-74 years: a population-based study. Cephalalgia. 2000;20(10):893–899. doi: 10.1046/j.1468-2982.2000.00133.x.
    1. Prencipe M, Casini AR, Ferretti C, Santini M, Pezzella F, Scaldaferri N, et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry. 2001;70(3):377–381. doi: 10.1136/jnnp.70.3.377.
    1. Wijeratne T, Tang HM, Crewther D, Crewther S. Prevalence of migraine in the elderly: a narrated review. Neuroepidemiology. 2019;52(1–2):104–110. doi: 10.1159/000494758.
    1. Herrero S, Guerrero AL, Ruiz M, Pedraza MI, Mulero P, Barón J, et al. Migraine in the elderly: clinical characteristics in a series of 71 cases. J Headache Pain. 2013;14(1):P152. doi: 10.1186/1129-2377-14-S1-P152.
    1. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. doi: 10.1046/j.1365-2125.2003.02007.x.
    1. Gonzalez-Hernandez A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalon CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol. 2018;14(1):25–41. doi: 10.1080/17425255.2018.1416097.
    1. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099–1142. doi: 10.1152/physrev.00034.2013.
    1. Kelman L. Migraine changes with age: IMPACT on migraine classification. Headache. 2006;46(7):1161–1171. doi: 10.1111/j.1526-4610.2006.00444.x.
    1. Bigal ME, Lipton RB. Migraine at all ages. Curr Pain Headache Rep. 2006;10(3):207–213. doi: 10.1007/s11916-006-0047-6.
    1. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13(9):885–892. doi: 10.1016/S1474-4422(14)70128-0.
    1. Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, et al. Effect of different doses of Galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187–193. doi: 10.1001/jamaneurol.2017.3859.
    1. Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. doi: 10.1186/s12883-018-1193-2.
    1. Kielbasa W, Quinlan T. Population pharmacokinetics of Galcanezumab, an anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J Clin Pharmacol. 2020;60(2):229–239. doi: 10.1002/jcph.1511.
    1. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS) Cephalalgia. 2011;31(3):301–315. doi: 10.1177/0333102410381145.
    1. Chong CD, Dodick DW, Schlaggar BL, Schwedt TJ. Atypical age-related cortical thinning in episodic migraine. Cephalalgia. 2014;34(14):1115–1124. doi: 10.1177/0333102414531157.
    1. Lisicki M, D'Ostilio K, Coppola G, Parisi V, de Noordhout AM, Magis D, et al. Age related metabolic modifications in the migraine brain. Cephalalgia. 2019;39(8):978–987. doi: 10.1177/0333102419828984.
    1. Neeb L, Bastian K, Villringer K, Israel H, Reuter U, Fiebach JB. Structural gray matter alterations in chronic migraine: implications for a progressive disease? Headache. 2017;57(3):400–416. doi: 10.1111/head.13012.
    1. Ho TW, Fan X, Rodgers A, Lines CR, Winner P, Shapiro RE. Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults. Cephalalgia. 2009;29(7):711–718. doi: 10.1111/j.1468-2982.2008.01788.x.
    1. Mould DR, Meibohm B. Drug development of therapeutic monoclonal antibodies. BioDrugs. 2016;30(4):275–293. doi: 10.1007/s40259-016-0181-6.
    1. Muralidharan KK, Kuesters G, Plavina T, Subramanyam M, Mikol DD, Gopal S, et al. Population pharmacokinetics and target engagement of Natalizumab in patients with multiple sclerosis. J Clin Pharmacol. 2017;57(8):1017–1030. doi: 10.1002/jcph.894.
    1. Long A, Chigutsa E, Wallin J. Population pharmacokinetics of Necitumumab in Cancer patients. Clin Pharmacokinet. 2017;56(5):505–514. doi: 10.1007/s40262-016-0452-x.
    1. Zhang Y, Wei X, Bajaj G, Barrett JS, Meibohm B, Joshi A, et al. Challenges and considerations for development of therapeutic proteins in pediatric patients. J Clin Pharmacol. 2015;55(Suppl 3):S103–S115. doi: 10.1002/jcph.382.
    1. Shemesh CS, Chanu P, Jamsen K, Wada R, Rossato G, Donaldson F, et al. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. J Immunother Cancer. 2019;7(1):314. doi: 10.1186/s40425-019-0791-x.
    1. Edlund H, Melin J, Parra-Guillen ZP, Kloft C. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin Pharmacokinet. 2015;54(1):35–80. doi: 10.1007/s40262-014-0208-4.
    1. Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592–599. doi: 10.1016/j.phrs.2016.07.015.
    1. Jin Y, Smith C, Monteith D, Brown R, Camporeale A, McNearney TA, et al. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial. Osteoarthr Cartil. 2018;26(12):1609–1618. doi: 10.1016/j.joca.2018.08.019.
    1. Paneni F, Diaz Canestro C, Libby P, Luscher TF, Camici GG. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol. 2017;69(15):1952–1967. doi: 10.1016/j.jacc.2017.01.064.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren